{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:37:02Z","timestamp":1784353022596,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011878","name":"Vlaamse regering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jhep.2012.09.032","type":"journal-article","created":{"date-parts":[[2012,10,6]],"date-time":"2012-10-06T15:15:36Z","timestamp":1349536536000},"page":"319-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model"],"prefix":"10.1016","volume":"58","author":[{"given":"Femke","family":"Heindryckx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Coulon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Terrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Casteleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Stassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Geerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Libbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Allemeersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Carmeliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Colle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Van Vlierberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2012.09.032_b0255","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0304-3835(98)00280-8","article-title":"The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line","volume":"135","author":"Huang","year":"1999","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhep.2012.09.032_b0010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2012.09.032_b0015","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2012.09.032_b0020","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jhep.2012.09.032_b0025","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jhep.2012.09.032_b0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00277-010-1027-9","article-title":"Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations","volume":"90","author":"Scholl","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jhep.2012.09.032_b0260","first-page":"8","article-title":"Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells","author":"Chen","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jhep.2012.09.032_b0265","first-page":"E45","article-title":"PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma- and melanoma cell lines","volume":"131","author":"Bender","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2012.09.032_b0045","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2010.11.011","article-title":"Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma","volume":"54","author":"Marijon","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.09.032_b0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1013172910858","article-title":"Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches","volume":"20","author":"Kerbel","year":"2001","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jhep.2012.09.032_b0055","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ejca.2008.11.038","article-title":"Resistance to EGF-R (erbB-1) and VEGF-R modulating agents","volume":"45","author":"Dempke","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2012.09.032_b0060","first-page":"101","article-title":"Resistance to angiogenesis inhibitors in renal cell carcinoma","volume":"9","author":"Tamaskar","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.jhep.2012.09.032_b0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.semcancer.2009.05.001","article-title":"Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance","volume":"19","author":"Cao","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jhep.2012.09.032_b0070","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-09-0095","article-title":"Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy","volume":"15","author":"Ebos","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2012.09.032_b0075","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2012.09.032_b0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0093-7754(01)90211-8","article-title":"Biological consequences of tumor hypoxia","volume":"28","author":"H\u00f6ckel","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jhep.2012.09.032_b0085","first-page":"E73","article-title":"The role of the hypoxia-inducible factor in tumor metabolism growth and invasion","volume":"93","author":"Brahimi-Horn","year":"2006","journal-title":"Bull Cancer"},{"key":"10.1016\/j.jhep.2012.09.032_b0090","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-10-1360","article-title":"Hypoxia and hypoxia-inducible factors: master regulators of metastasis","volume":"16","author":"Lu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2012.09.032_b0095","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/87904","article-title":"Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions","volume":"7","author":"Carmeliet","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2012.09.032_b0100","first-page":"2749","article-title":"Placental growth factor is a survival factor for tumor endothelial cells and macrophages","volume":"62","author":"Adini","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2012.09.032_b0105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","article-title":"Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels","volume":"131","author":"Fischer","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2012.09.032_b0110","doi-asserted-by":"crossref","first-page":"35172","DOI":"10.1074\/jbc.274.49.35172","article-title":"Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis","volume":"274","author":"Yonekura","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2012.09.032_b0115","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jhep.2011.04.015","article-title":"Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer","volume":"55","author":"Alpini","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.09.032_b0120","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2002-11-3423","article-title":"Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor","volume":"102","author":"Selvaraj","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2012.09.032_b0125","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2012.09.032_b0130","doi-asserted-by":"crossref","first-page":"25646","DOI":"10.1016\/S0021-9258(18)47298-5","article-title":"Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1\/KDR","volume":"269","author":"Park","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2012.09.032_b0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ccr.2010.11.009","article-title":"HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF","volume":"19","author":"Rolny","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2012.09.032_b0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2012.09.032_b0145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cell.2010.02.039","article-title":"Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease","volume":"141","author":"Van de Veire","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2012.09.032_b0150","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2613.2009.00656.x","article-title":"Experimental mouse models for hepatocellular carcinoma research","volume":"90","author":"Heindryckx","year":"2009","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.jhep.2012.09.032_b0155","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1476-4598-9-219","article-title":"Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma","volume":"9","author":"Heindryckx","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jhep.2012.09.032_b0160","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/MEG.0b013e3283554219","article-title":"Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model","volume":"24","author":"Heindryckx","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2012.09.032_b0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jhep.2012.02.021","article-title":"Effect of prolyl hydroxylase domain-2 haplodeficiency on hepatocarcinogenesis and progenitor cell activation","volume":"57","author":"Heindryckx","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.09.032_b0170","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.4049\/jimmunol.178.3.1357","article-title":"IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo","volume":"178","author":"Watkins","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2012.09.032_b0175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumor-educated macrophages promote tumor progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat Rev"},{"key":"10.1016\/j.jhep.2012.09.032_b0180","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3748\/wjg.v11.i11.1705","article-title":"Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival","volume":"11","author":"Huang","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2012.09.032_b0185","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1593\/neo.91880","article-title":"The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer","volume":"12","author":"Campbell","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.jhep.2012.09.032_b0190","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.ijrobp.2009.12.010","article-title":"Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation","volume":"76","author":"McGee","year":"2010","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.jhep.2012.09.032_b0270","first-page":"124","article-title":"Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore CTM), doxorubicin (Caelyx\u00ae) or vincristine","volume":"11","author":"Verreault","year":"2011","journal-title":"BMC"},{"key":"10.1016\/j.jhep.2012.09.032_b0275","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","article-title":"Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization","volume":"136","author":"Mazzone","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2012.09.032_b0205","first-page":"417","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat Rev"},{"key":"10.1016\/j.jhep.2012.09.032_b0210","first-page":"1647","article-title":"The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma","volume":"23","author":"Nagaoka","year":"2010","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jhep.2012.09.032_b0215","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2006.10.005","article-title":"Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma","volume":"250","author":"Ho","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jhep.2012.09.032_b0220","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ijc.25492","article-title":"Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue","volume":"128","author":"Xu","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2012.09.032_b0285","first-page":"39","article-title":"Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF","volume":"37","author":"Yao","year":"2007","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.jhep.2012.09.032_b0230","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1200\/JCO.2008.21.2522","article-title":"Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may","volume":"27","author":"Blanke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2012.09.032_b0235","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","article-title":"A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer","volume":"27","author":"Hecht","year":"2009","journal-title":"J Clin Oncol Soc Clin Oncol"},{"key":"10.1016\/j.jhep.2012.09.032_b0240","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","article-title":"Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy","volume":"13","author":"Dickson","year":"2007","journal-title":"Clin Caner Res"},{"key":"10.1016\/j.jhep.2012.09.032_b0245","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"P\u00e0ez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhep.2012.09.032_b0280","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812007647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812007647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:10:08Z","timestamp":1781111408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827812007647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0168827812007647"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2012.09.032","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2012.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}